- MSKCC’s James Allison is quoted in a Bloomberg News article about findings that show therapies like the Bristol drug, that prompt killer T-cells to eliminate invaders, may work against many tumors.
- In a New York Times article, Chaya S. Moskowitz, a biostatistician at MSKCC, indicates that the breast cancer risk for those treated with high radiation doses for Hodgkin’s lymphoma is similar to that for women with mutations in the BRCA1 gene.
- Dr. Clifford A. Hudis of MSKCC is quoted in a New York Times article about a study that shows a drug, known as T-DM1, that delivers a powerful poison to tumors without some of the side effects of traditional treatments can delay the worsening of breast cancer and also appears to substantially prolong lives.